CO2019002608A2 - Biomarcadores de arn para angioedema hereditario - Google Patents

Biomarcadores de arn para angioedema hereditario

Info

Publication number
CO2019002608A2
CO2019002608A2 CONC2019/0002608A CO2019002608A CO2019002608A2 CO 2019002608 A2 CO2019002608 A2 CO 2019002608A2 CO 2019002608 A CO2019002608 A CO 2019002608A CO 2019002608 A2 CO2019002608 A2 CO 2019002608A2
Authority
CO
Colombia
Prior art keywords
arn
biomarkers
hereditary angioedema
angioedema
hereditary
Prior art date
Application number
CONC2019/0002608A
Other languages
English (en)
Inventor
Daniel J Sexton
Ryan Faucette
Malini Viswanathan
Tripti Gaur
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of CO2019002608A2 publication Critical patent/CO2019002608A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En la presente se proporcionan los métodos y kits para analizar una muestra biológica obtenida de un sujeto que tenga, se sospeche de tener, o que esté en riesgo de una enfermedad asociada con el sistema de activación por contacto.
CONC2019/0002608A 2016-09-16 2019-03-21 Biomarcadores de arn para angioedema hereditario CO2019002608A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662395811P 2016-09-16 2016-09-16
PCT/US2017/051772 WO2018053260A1 (en) 2016-09-16 2017-09-15 Rna biomarkers for hereditary angioedema

Publications (1)

Publication Number Publication Date
CO2019002608A2 true CO2019002608A2 (es) 2019-03-29

Family

ID=60117738

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0002608A CO2019002608A2 (es) 2016-09-16 2019-03-21 Biomarcadores de arn para angioedema hereditario

Country Status (13)

Country Link
US (1) US11884979B2 (es)
EP (1) EP3513188A1 (es)
JP (2) JP7319916B2 (es)
KR (2) KR102569559B1 (es)
CN (2) CN109716129B (es)
AU (2) AU2017325999C1 (es)
BR (1) BR112019005172A2 (es)
CA (1) CA3036979A1 (es)
CO (1) CO2019002608A2 (es)
EA (1) EA201990730A1 (es)
IL (1) IL265200A (es)
MX (1) MX2019002929A (es)
WO (1) WO2018053260A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109716138B (zh) 2016-09-16 2023-10-03 武田药品工业株式会社 用于接触活化系统相关的疾病的蛋白生物标记
WO2018053247A1 (en) 2016-09-16 2018-03-22 Dyax Corp. Metabolite biomarkers for diseases associated with the contact activation system
CN111184734B (zh) * 2020-03-05 2021-04-27 北京市心肺血管疾病研究所 miRNA在治疗心肌肥厚中的应用
CN111518883B (zh) * 2020-04-02 2022-12-30 深圳大学 一种用于冠心病诊断的血浆miRNA标志物及其应用
CN113311056B (zh) * 2021-05-10 2022-06-21 中国医学科学院北京协和医院 用于遗传性血管水肿的标志物及其应用
CN113736896A (zh) * 2021-09-09 2021-12-03 中国医学科学院北京协和医院 用于预测遗传性血管性水肿发作的标志物及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795865A (en) 1994-01-11 1998-08-18 Dyax Corp. Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
EP1487857A4 (en) * 2002-03-07 2006-08-09 Ludwig Inst Cancer Res BLOOD AND LYMPHATIC ENDOTHELIAL CELL GENES
PT1531791E (pt) 2002-06-07 2010-12-16 Dyax Corp Prevenção e redução da isquémia
AU2002952993A0 (en) * 2002-11-29 2002-12-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic and diagnostic agents
WO2004063218A1 (en) * 2003-01-13 2004-07-29 Autogen Research Pty Ltd Obesity-related genes
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
JP5265923B2 (ja) * 2005-02-07 2013-08-14 ジーンニュース インコーポレーテッド 軽度の変形性関節症のバイオマーカーおよびその使用
CA2630838A1 (en) 2005-11-23 2007-05-31 Georg Dewald Detection and treatment of drug associated angioedema
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
US9096906B2 (en) 2007-03-27 2015-08-04 Rosetta Genomics Ltd. Gene expression signature for classification of tissue of origin of tumor samples
WO2009033185A1 (en) 2007-09-06 2009-03-12 University Of Massachusetts Virus-specific mirna signatures for diagnosis and therapeutic treatment of viral infection
PT3459564T (pt) 2010-01-06 2022-01-31 Takeda Pharmaceuticals Co Proteínas de ligação à calicreína plasmática
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
EP2563936B1 (en) 2010-04-29 2018-03-14 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
JP6012923B2 (ja) 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
JP6021893B2 (ja) 2011-04-18 2016-11-09 ディアミール, エルエルシーDiamir, Llc 軽度認知機能障害（ＭＣＩ）およびアルツハイマー病（ＡＤ）の早期検出ならびにモニタリングのために体液からのｍｉＲＮＡを使用する方法
EP2717923B1 (en) * 2011-06-10 2017-09-27 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US20130102485A1 (en) 2011-10-19 2013-04-25 Inhan Lee Method of Determining a Diseased State in a Subject
EP2890789A1 (en) * 2012-08-31 2015-07-08 Aptamir Therapeutics, Inc. Mirna modulators of chronic visceral inflammation
ES2790574T3 (es) * 2013-08-28 2020-10-28 Ionis Pharmaceuticals Inc Modulación de expresión de prekallikrein (PKK)
WO2015037656A1 (ja) 2013-09-11 2015-03-19 国立大学法人北海道大学 オートファジーを調節するマイクロｒｎａ
EP3808857A1 (en) * 2013-10-21 2021-04-21 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
US20160251720A1 (en) 2013-11-01 2016-09-01 The Trustees Of Columbia University In The City New York MicroRNA PROFILES IN HEART FAILURE: METHODS AND SYSTEMS FOR DETECTION AND USE
PL3096798T3 (pl) 2014-01-21 2021-07-26 Takeda Pharmaceutical Company Limited Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego
WO2015179909A1 (en) 2014-05-26 2015-12-03 The University Of Melbourne Mirna biomarkers of alzheimer's disease
US10370722B2 (en) 2014-05-30 2019-08-06 Toray Industries, Inc. Pancreatic cancer detection kit or device, and detection method
WO2016020626A1 (fr) 2014-08-07 2016-02-11 Galderma Research & Development microARNs CARACTÉRISANT L'ACNÉ ET LEURS UTILISATIONS
WO2016020625A1 (fr) 2014-08-07 2016-02-11 Galderma Research & Development Microarns caractérisant la rosacée et leurs utilisations
WO2016023077A1 (en) 2014-08-15 2016-02-18 Griffith University Biological markers
CN105527419A (zh) * 2014-12-11 2016-04-27 北京新华联协和药业有限责任公司 遗传性血管水肿的检测试剂盒及其制备方法
NZ733580A (en) * 2015-01-02 2024-02-23 Takeda Pharmaceuticals Co Bispecific antibodies against plasma kallikrein and factor xii
JP6694240B2 (ja) 2015-01-30 2020-05-13 ロート製薬株式会社 細胞の品質を評価する方法、及び細胞の品質判定キット
CN104651513B (zh) 2015-02-15 2018-03-27 青岛大学附属医院 一种痛风血清miRNAs生物标志物及其表达量的检测方法
WO2016139092A1 (en) 2015-03-04 2016-09-09 Hummingbird Diagnostics Gmbh Signature of health

Also Published As

Publication number Publication date
AU2017325999A1 (en) 2019-03-28
MX2019002929A (es) 2019-07-15
US20190241961A1 (en) 2019-08-08
JP2019528733A (ja) 2019-10-17
AU2017325999C1 (en) 2024-03-07
EP3513188A1 (en) 2019-07-24
CA3036979A1 (en) 2018-03-22
KR102569559B1 (ko) 2023-08-23
AU2017325999B2 (en) 2023-11-30
JP7319916B2 (ja) 2023-08-02
US11884979B2 (en) 2024-01-30
KR20230125104A (ko) 2023-08-28
NZ751439A (en) 2023-12-22
CN117187377A (zh) 2023-12-08
CN109716129B (zh) 2023-10-03
CN109716129A (zh) 2019-05-03
JP2023126649A (ja) 2023-09-07
EA201990730A1 (ru) 2019-08-30
IL265200A (en) 2019-05-30
KR20190045369A (ko) 2019-05-02
BR112019005172A2 (pt) 2019-07-02
AU2024201287A1 (en) 2024-03-14
WO2018053260A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
CO2019002608A2 (es) Biomarcadores de arn para angioedema hereditario
CO2019002607A2 (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contacto
GB2556004A (en) Markers of stroke and stroke severity
CO2017006740A2 (es) Anticuerpos anti–cd79b
BR112014031365A2 (pt) métodos de detectar doenças ou condições
MX2019007653A (es) Métodos para la optimización de ensayos rápidos de susceptibilidad antimicrobiana.
CL2020002103A1 (es) Anticuerpos anti-htra1 y metodos de uso de los mismos. (divisional solicitud 201801139)
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
BR112016006312A2 (pt) método e kit para determinar a presença ou ausência de staphylococcus aureus resistente à meticilina em uma amostra biológica
BR112016025627A2 (pt) biomarcadores e combinações dos mesmos para diagnóstico de tuberculose
ES2679289T3 (es) Procedimientos para el pronóstico y/o diagnóstico de una enfermedad neurodegenerativa, procedimientos para identificar compuestos candidatos y compuestos para tratar una enfermedad neurodegenerativa
CO2018001599A2 (es) Un inhibidor de anticuerpo monoclonal de factor xiia
BR112019006862A2 (pt) dispositivo de análise e método para testagem de uma amostra
CO2019006234A2 (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal
BR112017006315A2 (pt) agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits
BR112017021186A2 (pt) ?método para detectar a presença de bactérias produtoras de beta-lactamase?
BR112018009463A2 (pt) ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
CO2019002599A2 (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto
BR112017005474A2 (pt) normalização da resposta de um instrumento de fluorescência com o uso de resposta espectral
BR112019007121A2 (pt) cartucho, sistema de análise e método para testagem de uma amostra
BR112017002575A2 (pt) método para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo, kit e sistema para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo
AR121805A1 (es) Anticuerpo anti-cd47 y usos del mismo
FI20165148A (fi) Kaksoisfotoniviritteistä fluoresenssia hyödyntävä bioaffiniteettimääritysmenetelmä